Form 8-K CRISPR Therapeutics AG For: Oct 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Chardan Capital Markets Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
October 28, 2019 10:25 AM EDTChardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $72.50 price target on CRISPR Therapeutics (NASDAQ: CRSP) after the comapny announced 3Q19 results and provided updates on clinical programs, with dosing initiated in the phase I/II trial (NCT04035434) of allogeneic CAR-T CTX110 in CD19+ cancers, and the follow-on asset, CTX120, targeting BCMA set to... More
